Present status and tasks for future of point of care testing

This paper introduces Point-Of-Care Testing(POCT) developed by Bayer, mainly focusing on urine dipstick and tests for Diabetes Mellitus. Urinalysis using a dipstick has been widely carried out as a screening test for various kinds of diseases. Ten-pad urine dipstick is commercially available at the present time, and the desktop instruments have been developed for automatic optical reading, such as the Clinitek 50/100/500 systems. More recently, Bayer developed a new urine dipstick intended for reliable detection of the early stage of kidney disease without the influence of urine condensation or dilution. The dipstick adds 2 pads to conventional urine dipsticks: one for the measurement of small amounts of protein(albumin), and the other for creatinine. A semi-quantitative urine protein-to-creatinine ratio is based on these results. There have been significant advances made in blood glucose meters for POCT in terms of reliability, simplicity of operation, sample volume, etc. And not only healthcare professionals but also patients with diabetes have used POCT meters. Dexter-ZII is available as one of these meters. DCA2000 is a portable analyzer for measuring HbA1c in 6 min. Patients could be treated and instructed on the basis of HbA1c measured by DCA2000. As one of the tasks for the future, it is preferable that some POCT systems be available as OTC for ordinary people to manage their own health. Also, I emphasize that it is important to review the usability of conventional urine dipsticks like a check for drug side effects, as well as for developing new urine analyses.